Test Price
2,800 AED✅ Home Collection Available
MOGS Gene Glycosylation Disorder Type 2B Genetic Test in UAE | 2,800 AED | DHA-Licensed
Executive Summary & Core Metrics
This advanced genetic assay provides comprehensive analysis of the MOGS gene responsible for Congenital Disorder of Glycosylation Type IIb (CDG‑IIb) using Next‑Generation Sequencing (NGS) technology with a diagnostic sensitivity of 99.9%. Performed at a DHA‑licensed laboratory, the test ensures patient data confidentiality under UAE Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 on ICT in Health Fields. The price includes VIP mobile phlebotomy home collection with temperature‑controlled cold‑chain logistics (daily 8 AM–11 PM) and a post‑result tele-genetic counselling session. For insurance coverage verification, contact via WhatsApp +971 54 548 8731.
99.9% via ISO‑accredited NGS platform
VIP phlebotomy with cold‑chain logistics 8 AM–11 PM
Post‑result tele-counselling with specialist
Instant verification via WhatsApp +971 54 548 8731
Test Overview & Methodology
This molecular diagnostic test identifies pathogenic variants in the MOGS gene that cause Congenital Disorder of Glycosylation Type IIb (CDG‑IIb), a rare autosomal recessive metabolic disorder. The analysis achieves 99.9% diagnostic sensitivity and provides definitive molecular confirmation for clinical management, carrier screening, and family planning.
| Feature | Our Test (NGS) | Closest Alternative (Biochemical CDG Screen) |
|---|---|---|
| Precision | 99.9% mutation detection | Qualitative, no gene-level data |
| Methodology | Next‑Generation Sequencing (NGS) | Transferrin isoelectric focusing / Mass spectrometry |
| TAT | 3–4 weeks | 1–2 weeks |
| Clinical Actionability | Definitive diagnosis, carrier testing, prenatal options | Indicative only; requires genetic follow‑up |
Physician Insight & Safety Protocols
“MOGS‑related CDG type IIb is a rare multisystem condition that requires a multidisciplinary diagnostic approach. This NGS‑based test offers definitive molecular confirmation, but results should always be correlated with clinical presentation and biochemical markers. Pre‑test genetic counselling is essential, and post‑test discussion with a metabolic specialist is strongly advised. Please never alter or discontinue prescribed medications without consulting your treating physician.” – Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Advisory
Safety Exclusion Criteria & Emergency Red Flags
- Unstable acute illness or haemodynamic instability
- Inability to provide informed consent (legal guardian required for minors)
- Recent blood transfusion (within 4 weeks) may interfere with DNA analysis — please inform the laboratory
- Seek emergency care immediately if sudden neurological deterioration, seizures, or coma occur; this test is not intended for acute emergency diagnosis.
Patient FAQ & Clinical Guidance
1. What is the MOGS Gene Glycosylation Disorder Type 2B NGS Test?
This test uses next‑generation sequencing to detect pathogenic variants in the MOGS gene that cause Congenital Disorder of Glycosylation Type IIb with 99.9% diagnostic sensitivity. It provides comprehensive coverage of all coding regions and is the gold‑standard molecular analysis for CDG‑IIb, recommended for patients with clinical suspicion of a congenital disorder of glycosylation.
2. How is the sample collected and can I do it at home?
A certified phlebotomist collects a peripheral whole blood sample at your home through our VIP mobile phlebotomy service, operating daily from 8 AM to 11 PM. The sample is transported under ISO‑certified temperature‑controlled cold‑chain conditions and processed the same day to ensure maximum DNA integrity.
3. What do the results mean and how long does it take?
Results are reported within 3–4 weeks and classify variants as pathogenic, likely pathogenic, benign, or variants of uncertain significance. Post‑test genetic counselling is provided to help interpret findings. A negative result does not completely rule out CDG‑IIb if strong clinical suspicion remains; additional metabolic work‑up may be recommended.
4. Who should consider this genetic test?
This test is indicated for individuals with clinical features suggestive of a congenital disorder of glycosylation, including developmental delay, hypotonia, feeding difficulties, coagulopathy, and abnormal serum transferrin isoelectric focusing. It is also appropriate for carrier testing in families with known MOGS mutations and for prenatal diagnosis in at‑risk pregnancies.
5. How is my data protected under UAE law?
Your genetic data is processed and stored in full compliance with UAE Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 concerning the Use of Information and Communication Technology in Health Fields. All data is encrypted, access‑restricted, and never shared without your explicit consent.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance Framework
This diagnostic service operates under DHA Facility License No. 1143 and adheres to UAE Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) for all patient data handling. Clinical information systems comply with Federal Law No. 2 of 2019 on ICT in Health Fields. All genetic testing procedures follow the standards set by Federal Decree‑Law No. 4 of 2016 on Medical Liability, ensuring patient safety and informed consent protocols are rigorously maintained.
DNA Labs UAE applies enterprise‑grade encryption, role‑based access controls, and regular audit logging to safeguard genetic information. No data is transferred to third parties without explicit patient authorization. For concerns regarding data privacy, contact our Data Protection Officer at dpo@dnalabs.ae.
Clinical & Logistical Metadata
| Test Name | MOGS Gene Glycosylation Disorder Type 2B NGS Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood (Peripheral) |
| Methodology Used | Next‑Generation Sequencing (NGS) |
| ICD-10-CM Code | E77.8 |
| LOINC Code | 78925-4 |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians